Sevuparin

Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Sevuparin receives Rare Pediatric Disease Designation from FDA for the treatment of children with sickle cell disease

Dr. John Öhd appointed Chief Medical Officer at Modus Therapeutics

Learn more about our ongoing Phase 2 Study
SCD Therapeutics Conference, 2016

Modus colleagues presented our story at the 5th Annual Sickle Cell Disease Therapeutics conference in New York in October

Poster presented at ASH 2016
La Biotech Interview with Modus

Learn more about our study in the Middle East